Navigation Links
Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis

A Drug's Safety Profile is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., April 21 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that in addition to surveyed infectious disease specialists' prediction that empiric coverage of methicillin-resistant Staphylococcus aureus (MRSA) will increase, they foresee greater use of parenteral outpatient therapy (intravenous or intramuscular injection) for the treatment of osteomyelitis. Osteomyelitis is an infection of bone or bone marrow caused by bacterial infections.

"Osteomyelitis often requires an extended duration of antibiotic therapy after hospital discharge and many patients are prescribed an injectable agent," stated Lisa Arias, analyst at Decision Resources. "Nearly one-third of surveyed physicians expect increased use of parenteral antibiotic therapy in the next five years."

The new report entitled Hospital Anti-Infectives Insight Series: Osteomyelitis also finds that although surveyed infectious disease specialists look for a range of attributes when prescribing an antibiotic for osteomyelitis, the leading attribute, by far, is the drug's safety profile when administered over a long period of time -- 77 percent of surveyed physicians cited this attribute as extremely important. Physicians also look for an antibiotic that can be dosed, administered and monitored easily in the outpatient setting. Other important factors are the drug's ability to penetrate bone and activity against MRSA.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales              Elizabeth Marshall
    Decision Resources           Decision Resources, Inc.
    781-296-2691                 781-296-2563

SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
9. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Post Your Comments:
(Date:12/1/2015)... Wilmington, Delaware (PRWEB) , ... December 01, 2015 ... ... award winner at the 7th Annual 2015 Golden Bridge Business Awards under the ... is a zero capex web based sample management software that ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS ... care management and population health arenas, is pleased to announce that VIP Care ... services, has successfully implemented the ACUITY Complete Care™ Management to back their collaborative ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users can ... customization, the possibilities are truly endless, all with a click of a mouse. Each ... flip, horizontal flip, depth of field and more, all within Final Cut Pro X. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... market research report "Nucleic Acid Labeling Market by Product ... Translation, Random Primer, In Vitro Transcription, Reverse Transcription, End ... by MarketsandMarkets, The global market is expected to reach ... in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... 01, 2015 ... "Veterinary Equipment and Disposables Market by product, by ... to their offering. --> ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> Research and Markets ...
(Date:12/1/2015)... 1, 2015  Today, AmerisourceBergen, a ... CareFront, a first-of-its-kind population health management program focused ... Designed to be built into existing employer benefit ... resources for their care and explains how to ... tools to help patients understand their treatment options ...
Breaking Medicine Technology: